Question

A 28-year-old woman presents with fatigue, jaundice, and elevated liver enzymes. Autoimmune markers are positive for ANA and anti-smooth muscle antibody, and a liver biopsy confirms autoimmune hepatitis. She is started on corticosteroids. Which of the following drugs should be added to steroids to maintain remission and minimize steroid toxicity?

• A. Rituximab
• B. Mycophenolate mofetil
• C. Cyclophosphamide
• D. Azathioprine

Hint:

Standard Therapy for AIH:
Induction of Remission: Prednisone monotherapy OR Prednisone + Azathioprine.
Maintenance of Remission: Azathioprine monotherapy (steroids should be completely tapered off if clinically possible to avoid long-term toxicity).

Answer 1

The Correct Option is D

Concept:
A young woman is definitively diagnosed with Type 1 Autoimmune Hepatitis (AIH), confirmed by the classic presence of positive ANA and Anti-Smooth Muscle Antibodies (ASMA) alongside characteristic histological findings.
She has been appropriately initiated on acute induction therapy with systemic corticosteroids. The clinical objective now is to select the standard, first-line pharmacological agent to be added as a steroid-sparing maintenance therapy to preserve remission while avoiding the severe, long-term toxicities of chronic steroid use.
Explanation:
• Autoimmune Hepatitis (AIH) is a chronic, progressive, necroinflammatory disease of the liver driven by an aberrant auto-reactive immune response against hepatocytes.

• The absolute standard of care for the initial induction of remission in symptomatic AIH is monotherapy with high-dose corticosteroids (such as Prednisone or Prednisolone) or, alternatively, an initial combination regimen of steroids with an immunomodulator.

• Because the long-term, systemic administration of corticosteroids inevitably leads to severe, debilitating morbidities (including osteoporosis, severe weight gain, iatrogenic diabetes mellitus, hypertension, and overwhelming susceptibility to infection), establishing a steroid-sparing maintenance regimen is a critical long-term goal.

• Azathioprine (Option D) is universally established as the standard, first-line antimetabolite immunomodulator used explicitly for this purpose.

• It is routinely added to the regimen early on, allowing clinicians to gradually and safely taper the corticosteroid dose down to zero, eventually maintaining the patient on Azathioprine monotherapy to sustain long-term remission.

• Mycophenolate mofetil (Option B) is indeed a highly effective immunosuppressant, but it is currently recommended only as a second-line rescue agent for patients who are either completely intolerant to Azathioprine or who fail to achieve remission on the standard regimen.

• Rituximab (Option A) and Cyclophosphamide (Option C) are potent, highly toxic immunosuppressants generally reserved for severe vasculitides or aggressive rheumatological conditions, and they do not have a standard role in the routine, primary maintenance therapy of uncomplicated AIH.
Final Answer:
Azathioprine is the standard first-line immunomodulator added to effectively maintain remission and facilitate successful steroid tapering in Autoimmune Hepatitis.